Antibody–Drug Conjugates in Cancer Therapy

Antibody–Drug Conjugates in Cancer Therapy

Innovative drugs designed for oncotherapy are antibody-drug conjugates (ADCs), constructed with monoclonal antibodies, linkers, and natural cytotoxins. Over the past few years, ADCs have had considerable success due to the distinctive benefits of both chemotherapy drugs and antibody drugs. The rapid R&D of ADCs is being accelerated by the production of highly specific antibodies, novel applications of marine toxins, and revolutionary linker technologies. Meanwhile, for potential ADCs, some problems remain to be solved. For example, site-specific conjugation varieties have been suggested to solve the inhomogeneity of DARs (Drug Antibody Ratios). The use of various natural toxins, especially marine cytotoxins, and the development strategies for ADCs over the past decade are summarized in this analysis. Representative ADCs are implemented and characterized with their new features with marine cytotoxins in the pipeline, whilst perspective comments are proposed for future ADCs. To some extent, site-specific conjugation technology has caught the attention of multiple pharmaceutical companies to solve the problem of inhomogeneity, pointing out the path to further ADC growth. With the development of conjugation technology, through the diversified modification of linkers, a range of conjugated groups have been designed and connected to several different drugs.

Author (s) Details

Xiaoling Lu
The Faculty of Basic Medical Science, Naval Medical University, Shanghai, 200433, China.

Yujie Wang
The Faculty of Basic Medical Science, Naval Medical University, Shanghai, 200433, China and Institute of Clinical Science, Zhongshan Hospital, Shanghai Medical School, Fudan University, Shanghai 200032, China.

Xin Cao
Institute of Clinical Science, Zhongshan Hospital, Shanghai Medical School, Fudan University, Shanghai 200032, China.

Yuping Zhu
The Faculty of Basic Medical Science, Naval Medical University, Shanghai, 200433, China.

View Book :- https://stm.bookpi.org/HMMR-V1/issue/view/2

Editor 251News

leave a comment

Create Account



Log In Your Account